Get started
Author

Andreas Mueller

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
2017 · Marco Colleoni, Weixiu Luo, et al. · The Lancet Oncology · 122
World Congress Integrative Medicine & Health 2017: Part one
2017 · Benno Brinkhaus, Torkel Falkenberg, et al. · BMC Complementary and Alternative Medicine · 119
PDF
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08
2015 · Khalil Zaman, Ralph Winterhalder, et al. · European Journal of Cancer · 55
The effects of an integrated supportive care intervention on quality of life outcomes in outpatients with breast and gynecologic cancer undergoing chemotherapy: Results from a randomized controlled trial
2019 · Nadja Klafke, Cornelia Mahler, et al. · Cancer Medicine · 40
PDF
Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast Cancer
2023 · Walter P. Weber, Zoltan Matrai, et al. · JAMA Surgery · 29
PDF
Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer
2007 · B Klaeser, O Wiederkehr, et al. · Annals of Oncology · 26
PDF
Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
2023 · Walter P. Weber, Martin Heidinger, et al. · Annals of Surgical Oncology · 23
PDF
Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
2017 · Bernhard C. Pestalozzi, Christoph Tausch, et al. · BMC Cancer · 17
PDF
SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial.
2014 · Christoph Rochlitz, Roger von Moos, et al. · Journal of Clinical Oncology · 14
Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
2023 · Christoph Tausch, Kavitha Däster, et al. · Breast Cancer Research and Treatment · 12
PDF
Incidence of hypocalcemia in patients with castration-resistant prostate cancer treated with denosumab: Data from a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every four weeks (q4w) versus every 12 weeks (q12w)—SAKK 96/12 (REDUSE).
2019 · Silke Gillessen, Roger Anton Fredy Von Moos, et al. · Journal of Clinical Oncology · 12
Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (OPBC-03/SAKK 23/16/IBCSG 57-18/ABCSG-53/GBG-101-TAXIS).
2024 · Walter Paul Weber, Zoltan Matrai, et al. · Journal of Clinical Oncology · 9
PDF
Is There Really Enough Evidence to Abandon Surgery After Radiation Chemotherapy in Esophageal Cancer?
2005 · Thomas Ruhstaller, Andreas Mueller, et al. · Journal of Clinical Oncology · 9
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)
2025 · L. Malorni, S. Tyekucheva, et al. · Annals of Oncology · 8
ENGOT-ov54/Swiss-GO-2/MATAO including LOGOS (Low-Grade Ovarian cancer Sub-study): MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer—A randomized, double-blinded, placebo-controlled, multicenter phase III Trial.
2021 · Viola A. Heinzelmann-Schwarz, Christian Kurzeder, et al. · Journal of Clinical Oncology · 7
Prevention of palmoplantar erythrodysesthesia (PPE) with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (PLD), a placebo-controlled, double blinded, phase lll trial (SAKK 92/08).
2012 · Thomas Ruhstaller, Karin Ribi, et al. · Journal of Clinical Oncology · 4
Abstract RF1-02: Palbociclib plus letrozole versus weekly paclitaxel, both in combination w/ trastuzumab plus pertuzumab, as neoadjuvant treatment for patients w/ HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)
2025 · Luca Malorni, S. Tyekucheva, et al. · Clinical Cancer Research · 3
Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14]
2022 · Ursula Hasler-Strub, Andreas Mueller, et al. · Journal of Geriatric Oncology · 2
PDF
An open-label, multicenter biomarker-oriented phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
2011 · M Moehler, A Mueller, et al. · Zeitschrift für Gastroenterologie · 2
Incidence of osteonecrosis of the jaw (ONJ) in the randomized non-inferiority phase III trial SAKK 96/12 REDUSE comparing denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w).
2024 · Roger Anton Fredy Von Moos, Andreas Mueller, et al. · Journal of Clinical Oncology · 1
PDF
Weekly docetaxel rechallenge in patients with hormone-resistant prostate cancer refractory to conventionally three weekly docetaxel.
2010 · S. Fuxius, A. Mueller, et al. · Journal of Clinical Oncology · 1
3298 Quality Assurance of Radiotherapy in the TAXIS-Trial (OPBC-03): Experiences with Dummy Run Procedures and Consequences for Future Randomized Trials
2026 · Guido Henke, Anna-Lena Eberhardt, et al. · Radiotherapy and Oncology
ASO Visual Abstract: Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
2023 · Walter P. Weber, Martin Heidinger, et al. · Annals of Surgical Oncology
Prospective identification of prognostic factors for patients with early failure of advanced ovarian cancer who undergo primary cytoreductive surgery followed by chemotherapy: The AGO-OVAR 19/FRAGILE study (NCT02828618).
2022 · Felix Hilpert, Alexander Burges, et al. · Journal of Clinical Oncology
Abstract OT-37-01: Ribociclib-endocrine therapy (ET) combination versus chemotherapy as 1st line treatment in patients (pts) with visceral metastatic breast cancer (BC). A multicenter, randomized phase III trial: SAKK 21/18
2021 · Michael Schwitter, Khalil Zaman, et al. · Cancer Research
Works count: 29
Citation count: 515
H-index: 11
I10-index: 11
Year
Topic
Type